Our dengue vaccine candidate, DSV4, comprises a part of the dengue envelope protein-EDIII region from all four serotypes fused with Hepatitis B surface antigen (HBsAg) for its self-assembly into a VLP (16). This evidence concerns the gene ERVW-1 and dengue disease.